[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] ZHU YJ,ZHENG B,WANG HY,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer［J］.Acta Pharmacologica Sinica,2017,38(5):614-622.
[3] NIU LL,LIU LP,YANG SL,et al.New insights into sorafenib resistance in hepatocellular carcinoma:Responsible mechanisms and promising strategies［J］.Biochimica et Biophysica Acta:Reviews on Cancer,2017,1868(2):564-570.
[4] LAI YT,FENG B,ABUDOUREYIMU M,et al.Non-coding RNAs:Emerging regulators of sorafenib resistance in hepatocellular carcinoma［J］.Frontiers in Oncology,2019,9:1156.
[5] WEI L,WANG XU,LV LY,et al.The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma［J］.Molecular Cancer,2019,18(1):147.
[6] YANG X,LIU M,LI MM,et al.Epigenetic modulations of noncoding RNA:a novel dimension of cancer biology［J］.Molecular Cancer,2020,19(1):64.
[7] QIAN XY,ZHAO JY,YEUNG PY,et al.Revealing lncRNA structures and interactions by sequencing-based approaches［J］.Trends in Biochemical Sciences,2019,44(1):33-52.
[8] HUANG Z,ZHOU JK,PENG Y,et al.The role of long noncoding RNAs in hepatocellular carcinoma［J］.Molecular Cancer,2020,19(1):77.
[9] LI CY,YANG JF,LIU CJ,et al.Long non-coding RNAs in hepatocellular carcinoma:Ordering of the complicated lncRNA regulatory network and novel strategies for HCC clinical diagnosis and treatment［J］.Pharmacological Research,2020,158:104848.
[10] HUANG XL,GAO Y,QIN JJ,et al.lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214［J］.American Journal of Physiology.Gastrointestinal and Liver Physiology,2018,314(5):G559-G565.
[11] LI X,LEI Y,WU M,et al.Regulation of macrophage activation and polarization by HCC-derived exosomal lncRNA TUC339［J］.International Journal of Molecular Sciences,2018,19(10):2958.
[12] SIMPSON D,KEATING GM.Sorafenib:in hepatocellular carcinoma［J］.Drugs,2008,68(2):251-258.
[13] ITO Y,TAKEDA T,SAKON M,et al.Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma［J］.British Journal of Cancer,2001,84(10):1377-1383.
[14] FAN GH,WEI XY,XU X.Is the era of sorafenib over? A review of the literature［J］.Therapeutic Advances in Medical Oncology,2020,12:1758835920927602.
[15] ZHI YR,ABUDOUREYIMU M,ZHOU H,et al.FOXM1-mediated LINC-ROR regulates the proliferation and sensitivity to sorafenib in hepatocellular carcinoma［J］.Molecular Therapy:Nucleic Acids,2019,16:576-588.
[16] SONG W,ZHENG CQ,LIU M,et al.TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p［J］.Molecular Therapy,2021,29(8):2601-2616.
[17] LIU ZF,LU J,FANG H,et al.m6A modification-mediated DUXAP8 regulation of malignant phenotype and chemotherapy resistance of hepatocellular carcinoma through miR-584-5p/MAPK1/ERK pathway axis［J］.Frontiers in Cell and Developmental Biology,2021,9:783385.
[18] CALVISI DF,LADU S,CONNER EA,et al.Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer［J］.Journal of Hepatology,2011,54(2):311-319.
[19] JIN WD,CHEN L,CAI X,et al.Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1［J］.Oncology Reports,2017,37(1):273-280.
[20] CHEN Y,LIN Y,SHU YQ,et al.Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer［J］.Molecular Cancer,2020,19(1):94.
[21] LI BW,JIANG JW,ASSARAF YG,et al.Surmounting cancer drug resistance:New insights from the perspective of N6-methyladenosine RNA modification［J］.Drug Resistance Updates:Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy,2020,53:100720.
[22] KONG HF,SUN J,ZHANG W,et al.Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3［J］.Bioengineered,2022,13(2):3108-3121.
[23]LIU YT,LIU GQ,HUANG JM.FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p-CCNG1 interaction network［J］.Bioscience Reports,2020,40(12):BSR20202054.
[24] SONG YN,HE SF,MA X,et al.RBMX contributes to hepatocellular carcinoma progression and sorafenib resistance by specifically binding and stabilizing BLACAT1［J］.American Journal of Cancer Research,2020,10(11):3644-3665.
[25] WU YF,ZHANG JG,ZHANG X,et al.Cancer stem cells:a potential breakthrough in HCC-targeted therapy［J］.Frontiers in Pharmacology,2020,11:198.
[26] LYTLE NK,BARBER AG,REYA T.Stem cell fate in cancer growth,progression and therapy resistance［J］.Nature Reviews:Cancer,2018,18(11):669-680.
[27] HIN TANG JJ,HAO THNG DK,LIM JJ,et al.JAK/STAT signaling in hepatocellular carcinoma［J］.Hepatic Oncology,2020,7(1):HEP18.
[28] YANG C,CAI WC,DONG ZT,et al.lncARSR promotes liver cancer stem cells expansion via STAT3 pathway［J］.Gene,2019,687:73-81.
[29] LIU Y,CHEN LM,YUAN HB,et al.LncRNA DANCR promotes sorafenib resistance via activation of IL-6/STAT3 signaling in hepatocellular carcinoma cells［J］.OncoTargets and Therapy,2020,13:1145-1157.
[30] CHENG ZJ,LEI ZQ,YANG PH,et al.Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway［J］.Gene,2019,684:95-103.
[31] SHEN Q,JIANG SH,WU MY,et al.LncRNA HEIH confers cell sorafenib resistance in hepatocellular carcinoma by regulating miR-98-5p/PI3K/AKT pathway［J］.Cancer Management and Research,2020,12:6585-6595.
[32] CHEN SW,XIA XH.Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met［J］.Journal of Cellular Physiology,2019,9aPta1:14999-15009.
[33] NIU YX,TANG GE,WU XL,et al.LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis［J］.Saudi Journal of Gastroenterology,2020,26(4):194-203.
[34] LI WD,DONG XS,HE CJ,et al.LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells［J］.Journal of Experimental & Clinical Cancer Research:CR,2019,38(1):183.
[35] SUN Y,WEI G,LUO H,et al.The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes［J］.Oncogene,2017,36(49):6774-6783.
[36] ZHOU YP,HUANG YG,DAI T,et al.LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1［J］.Biomedicine & Pharmacotherapy,2021,133:111030.
[37] TANG SY,TAN G,JIANG X,et al.An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells［J］.Oncotarget,2016,7(45):73257-73269.
[38] HUANG R,WU G,ZHENG B,et al.Long non-coding RNA CASC2 reduces sorafenib resistance in hepatocellular carcinoma cells via inhibition of miR-21-mediated PI3K/AKT pathways［J］.International Journal of Clinical and Experimental Medicine,2019,12(3):2301-2309.
[39] FAN L,HUANG X,CHEN J,et al.Long noncoding RNA MALAT1 contributes to sorafenib resistance by targeting miR-140-5p/Aurora-A signaling in hepatocellular carcinoma［J］.Molecular Cancer Therapeutics,2020,19(5):1197-1209.
[40] ZHOU M,ZHANG G,HU J,et al.Rutin attenuates sorafenib-induced chemoresistance and autophagy in hepatocellular carcinoma by regulating BANCR/miRNA-590-5P/OLR1 axis［J］.International Journal of Biological Sciences,2021,17(13):3595-3607.
[41] TANG Q,LI XJ,CHEN Y,et al.Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway［J］.Molecular Carcinogenesis,2022,61(4):417-432.
[42] LI XY,ZHOU Y,YANG L,et al.LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma［J］.Journal of Cellular Physiology,2020,235(4):3402-3413.
[43] SHI Y,YANG XH,XUE XF,et al.HANR enhances autophagy-associated sorafenib resistance through miR-29b/ATG9A axis in hepatocellular carcinoma［J］.OncoTargets and Therapy,2020,13:2127-2137.
[44] CHEN LX,SUN LB,DAI XF,et al.LncRNA CRNDE promotes ATG4B-mediated autophagy and alleviates the sensitivity of sorafenib in hepatocellular carcinoma cells［J］.Frontiers in Cell and Developmental Biology,2021,9:687524.
[45] GUO ZL,ZHANG J,FAN LL,et al.Long noncoding RNA (lncRNA) small nucleolar RNA host gene 16 (SNHG16) predicts poor prognosis and sorafenib resistance in hepatocellular carcinoma［J］.Medical Science Monitor,2019,25:2079-2086.
[46] JING Z,YE XP,MA XJ,et al.SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma［J］.Cancer Medicine,2020,9(12):4324-4338.
[47] YE JF,ZHANG RY,DU XH,et al.Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p［J］.OncoTargets and Therapy,2019,12:415-422.
[48] SUI CJ,DONG ZT,YANG C,et al.LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma［J］.Journal of Cellular and Molecular Medicine,2019,23(9):6024-6033.
[49] WU MY,SHEN XY,TANG YP,et al.Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells［J］.PeerJ,2020,8:e8624.
[50] TANG XF,ZHANG WC,YE YF,et al.LncRNA HOTAIR contributes to sorafenib resistance through suppressing miR-217 in hepatic carcinoma［J］.BioMed Research International,2020,2020:9515071.
[51] XU YZ,LIU YH,LI ZR,et al.Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675［J］.Oncology Reports,2020,44(1):165-173.
[52] QUAGLIATA L,QUINTAVALLE C,LANZAFAME M,et al.High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models［J］.Laboratory Investigation:a Journal of Technical Methods and Pathology,2018,98(1):95-105.
[53] ZHANG PF,WANG F,WU J,et al.LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma［J］.Journal of Cellular Physiology,2019,234(3):2788-2794.
[54] CHEN BW,ZHOU Y,WEI T,et al.lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p［J］.Journal of Cellular Biochemistry,2021,122(1):130-142.
[55] LIN JC,YANG PM,LIU TP.PERK/ATF4-dependent ZFAS1 upregulation is associated with sorafenib resistance in hepatocellular carcinoma cells［J］.International Journal of Molecular Sciences,2021,22(11):5848.
[56] KALBASI A,RIBAS A.Tumour-intrinsic resistance to immune checkpoint blockade［J］.Nature Reviews.Immunology,2020,20(1):25-39.
[57] ZHANG JL,ZHAO XH,MA XJ,et al.KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells［J］.International Journal of Molecular Medicine,2020,46(5):1794-1804.
[58] PENG LR,CHEN YY,OU QP,et al.LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma［J］.International Immunopharmacology,2020,89(Pt A):107071.
[59] CEBALLOS MP,RIGALLI JP,CERE LI,et al.ABC transporters:regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma［J］.Current Medicinal Chemistry,2019,26(7):1224-1250.
[60] TAKAHASHI K,YAN IK,WOOD J,et al.Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy［J］.Molecular Cancer Research,2014,12(10):1377-1387.
[61] TANDIA M,MHIRI A,PAULE B,et al.Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2):monocentric study［J］.Cancer Chemotherapy and Pharmacology,2017,79(4):759-766.
[62] CHEN YT,XIANG D,ZHAO XY,et al.Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance［J］.Human Cell,2021,34(6):1800-1811.